Skip to main content

CAPR

Stock
Health Care
Biotechnology

Performance overview

CAPR Price
Price Chart

Forward-looking statistics

Beta
0.89
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.

Company info

SectorHealth Care
IndustryBiotechnology
Employees87
Market cap$166.7M

Fundamentals

Enterprise value$310.4M
Revenue$17.4M
Revenue per employee—
Profit margin0.00%
Debt to equity0.98

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.37
Dividend per share—
Revenue per share$0.45
Avg trading volume (30 day)$20M
Avg trading volume (10 day)$30M
Put-call ratio—

Macro factor sensitivity

Growth-0.4
Credit+5.9
Liquidity-1.7
Inflation-1.8
Commodities+0.0
Interest Rates+0.2

Valuation

Dividend yield0.00%
PEG Ratio-12.65
Price to sales26.98
P/E Ratio-12.65
Enterprise Value to Revenue17.87
Price to book3.67

Upcoming events

Next earnings dayMay 14, 2025
Next dividend day—
Ex. dividend day—

News

Capricor's Lead Duchenne Therapy Hits FDA Regulatory Roadblock

Capricor Therapeutics Inc. CAPR stock is trading lower on Friday.

Benzinga (July 11, 2025)
Frequency Electronics, Capricor Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling around 300 points on Friday.

Benzinga (July 11, 2025)
Capricor (CAPR) Moves 20.4% Higher: Will This Strength Last?

Capricor (CAPR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Investment Research (June 25, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free